Last reviewed · How we verify
MMP with 5-FU
MMP with 5-FU is a topical combination therapy that uses matrix metalloproteinase modulation alongside 5-fluorouracil chemotherapy to treat skin lesions.
MMP with 5-FU is a topical combination therapy that uses matrix metalloproteinase modulation alongside 5-fluorouracil chemotherapy to treat skin lesions. Used for Actinic keratosis (presumed, based on 5-FU indication), Other skin lesions (specific indications not clearly documented).
At a glance
| Generic name | MMP with 5-FU |
|---|---|
| Also known as | 5-fluorouracil, drug delivery, drug infusion, microinfusion of medication percutaneously, MMP |
| Sponsor | Clinica Dermatologica Arbache ltda |
| Drug class | Topical chemotherapy combination |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Oncology |
| Phase | FDA-approved |
Mechanism of action
This combination leverages 5-FU's cytotoxic effects on rapidly dividing cells (commonly used in actinic keratosis and other skin cancers) while MMP (matrix metalloproteinase) components may modulate tissue remodeling and enhance drug penetration or efficacy. The exact mechanism of the MMP component in this formulation is not well-characterized in standard literature, suggesting this may be a proprietary or regional formulation.
Approved indications
- Actinic keratosis (presumed, based on 5-FU indication)
- Other skin lesions (specific indications not clearly documented)
Common side effects
- Local irritation/erythema
- Photosensitivity
- Burning/stinging at application site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMP with 5-FU CI brief — competitive landscape report
- MMP with 5-FU updates RSS · CI watch RSS
- Clinica Dermatologica Arbache ltda portfolio CI